🧠 Food for thought

Implications, context, and why it matters.

Starget’s funding ties to an AI-powered drug design platform

• Starget built an AI-driven drug design system called Backbone Dynamics 1.
• Backbone Dynamics uses proprietary backbone cyclization, a method that “locks” a peptide into a more rigid shape, to improve peptide radioligands’ stability, selectivity, and pharmacokinetics (how a drug moves through the body) 1.
• Its lead candidate, DOTA-PTR-58, targets somatostatin receptor type 3 (SSTR-3). SSTR-3 is highly expressed across tumor types that include sarcoma, melanoma, neuroendocrine tumors (NET), and hepatocellular carcinomas 1.
• Starget says SSTR-3 has lower expression in normal tissues than the more commonly used target SSTR-2, which the company expects could support a broader therapeutic window (a bigger gap between an effective dose and a harmful one) 1.

The deal signals shifts in biotech translation, supply chains, and state investment

• Starget says it will keep in silico (computer-based) AI-driven drug discovery in Israel, while building U.S. translational infrastructure through work with Louisiana’s Center for Molecular Imaging and Therapy (CMIT). Translational infrastructure moves a therapy from lab research into human testing 2.
• It also signed a supply agreement with isotope producer Nusano, a company that manufactures medical isotopes. The agreement is expected to cover isotope needs from discovery through commercialization, including rare alpha particle emitters such as Actinium-225, Astatine-211, and Lead-212 3.
• The Louisiana Growth Fund is a public-private investment vehicle launched by Louisiana Economic Development’s Louisiana Innovation (LA.IO) department to back companies that build long-term economic value in the state 2.